LNA Santé stock: fair value
LNA.PAThe fair value of LNA Santé under our model is $58.02, the price is 50% below.
The fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
Possible value trapIn our model the price counts as cheap below $44.63 and expensive above $82.89 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $62.47 (cash-flow model) and $53.58 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 11.7%. At 12.7% the fair value would be $54.94, at 10.7% it would be $61.88.
Possible value trap: looks cheap, but high risk.
Where the number comes from
Half from the cash-flow model, half from earnings times the industry P/E (19.6).
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 2.8%. Discounted at 11.7% (government bond yield 2.8% plus beta 2 times a risk premium of 4.5%); no analyst estimates were available.
Calculate with your own assumptionsThe calculation step by step
With these figures the cash flow model arrives at $62.47 per share: free cash flow for the next ten years, each year discounted to today at 11.7%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 11.7%) |
|---|---|---|---|---|
| 2026 | $63.28M | extrapolated at −2.9% | 0.8953 | $56.65M |
| 2027 | $62.53M | extrapolated at −1.2% | 0.8015 | $50.12M |
| 2028 | $62.54M | extrapolated at 0.0% | 0.7175 | $44.87M |
| 2029 | $63.06M | extrapolated at 0.8% | 0.6424 | $40.51M |
| 2030 | $63.96M | extrapolated at 1.4% | 0.5751 | $36.78M |
| 2031 | $65.13M | extrapolated at 1.8% | 0.5149 | $33.53M |
| 2032 | $66.51M | extrapolated at 2.1% | 0.4609 | $30.65M |
| 2033 | $68.05M | extrapolated at 2.3% | 0.4126 | $28.08M |
| 2034 | $69.72M | extrapolated at 2.5% | 0.3694 | $25.75M |
| 2035 | $71.5M | extrapolated at 2.6% | 0.3307 | $23.65M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $370.59M |
| Terminal value: cash flow 2035 × (1 + 2.8%) / (11.7% − 2.8%) | $823.8M |
| Present value of terminal value (× 0.3307) | $272.45M |
| Equity value (sum plus present value of terminal value) | $643.05M |
| Shares (diluted) | 10.29M |
| Value per share (equity value divided by shares) | $62.47 |
| Earnings per share, last twelve months | $2.73 |
| × 19.6 (industry P/E) | $53.58 |
| Fair value (average of both parts) | $58.02 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Feb 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.